Literature DB >> 3300762

Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.

L Specht, A M Nordentoft, S Cold, N T Clausen, N I Nissen.   

Abstract

One hundred and forty-two patients with Hodgkin's disease PS I or II were treated with total or subtotal nodal irradiation as part of a prospective randomized trial in the Danish National Hodgkin Study during the period 1971-83. They were followed till death or--at the time of this analysis--from 15 to 146 months after initiation of therapy. The initial tumour burden of each patient was assessed, combining tumour size of each involved region and number of regions involved. Tumour burden thus assessed proved to be the single most important prognostic factor with regard to disease free survival. Other known prognostic factors such as number of involved regions, mediastinal size, pathological stage, systemic symptoms, and ESR were related to tumour burden and lost their prognostic significance in a multivariate analysis. The only other factors of independent significance were histologic subtype and, to a lesser extent, sex. Combining tumour burden and histologic subtype made it possible to single out a group of patients with a very poor disease free survival. These patients also had a poorer survival from Hodgkin's disease and thus clearly candidates for additional initial treatment.

Entities:  

Mesh:

Year:  1987        PMID: 3300762      PMCID: PMC2001736          DOI: 10.1038/bjc.1987.109

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Prognostic significance of mediastinal mass in adult Hodgkin's disease.

Authors:  P J Schomberg; R G Evans; M J O'Connell; W L White; P M Banks; D M Ilstrup; J D Earle
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

Review 2.  Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis.

Authors:  H S Kaplan
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

3.  Hodgkin's disease, stages I and II: relationship of recurrence to size of disease, radiation dose, and number of sites involved.

Authors:  T L Thar; R R Million; R J Hausner; M H McKetty
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

4.  Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy.

Authors:  C K Lee; C D Bloomfield; A I Goldman; S H Levitt
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

5.  The pathology and nomenclature of Hodgkin's disease.

Authors:  R J Lukes; J J Butler
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

6.  The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience.

Authors:  R T Hoppe; C N Coleman; R S Cox; S A Rosenberg; H S Kaplan
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

7.  Prognostic factors in Hodgkin's disease with special reference to age.

Authors:  C Wedelin; M Björkholm; P Biberfeld; G Holm; B Johansson; H Mellstedt
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

8.  Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease.

Authors:  P Mauch; D Gorshein; J Cunningham; S Hellman
Journal:  Cancer Treat Rep       Date:  1982-04

9.  Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease.

Authors:  N I Nissen; A M Nordentoft
Journal:  Cancer Treat Rep       Date:  1982-04

10.  Prognostic significance of tumour burden in Hodgkin's disease PS I and II.

Authors:  L Specht; N I Nissen
Journal:  Scand J Haematol       Date:  1986-04
View more
  1 in total

Review 1.  [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.

Authors:  Salim Kanoun; Cedric Rossi; Olivier Casasnovas
Journal:  Cancers (Basel)       Date:  2018-05-18       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.